Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "adults"

927 News Found

Dr. Reddy's receives positive CHMP opinion from EMA for denosumab 'AVT03'
News | September 24, 2025

Dr. Reddy's receives positive CHMP opinion from EMA for denosumab 'AVT03'

Prolia is a prescription medicine used to treat osteoporosis in women


AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
Drug Approval | September 24, 2025

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population


FDA approves Merck's Keytruda injection for cancer therapy
Drug Approval | September 21, 2025

FDA approves Merck's Keytruda injection for cancer therapy

Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute


Novo Nordisk’s Wegovy delivered 16.6% weight loss
News | September 18, 2025

Novo Nordisk’s Wegovy delivered 16.6% weight loss

Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight


Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
News | September 16, 2025

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke


Rona submits IND for GalNAc-conjugated siRNA targeting obesity
Drug Approval | September 16, 2025

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options


Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC
Clinical Trials | September 16, 2025

Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC

Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone


Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
Clinical Trials | September 16, 2025

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management